Human proislet peptide - CureDM

Drug Profile

Human proislet peptide - CureDM

Alternative Names: HIP2B; Pancreate

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator CureDM
  • Class Antihyperglycaemics; Peptide fragments
  • Mechanism of Action Cell differentiation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus
  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 19 Sep 2016 CureDM completes a phase I clinical trial in Type-2 diabetes mellitus (Treatment-experienced) in USA (SC) (NCT01933256)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In volunteers) in USA (SC, Injection)
  • 03 Mar 2016 Human proislet peptide - CureDM is available for licensing as of 03 Mar 2016. http://www.curedm.com/partnership.php
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top